Search - tctmd.com

Displaying 41 - 60 of 144

Sort: Relevancy | Date

News Industry News

Intact Vascular’s Tack Endovascular System® Receives FDA Approval

April 16, 2019

News Conference News CRT 2019

CABG vs PCI in Left Main Disease: The Debate Continues

Yael L. Maxwell

March 12, 2019

News Industry News

Robocath obtains CE marking for R-One™, its robotic-assisted solution for treating coronary diseases

February 26, 2019

News Features

Top News in Coronary Artery Disease: 2018

Yael L. Maxwell

December 28, 2018

News Conference News AHA 2018

Long-term FREEDOM: At Nearly 8 years, CABG Maintains Mortality Benefit Over PCI

Michael O'Riordan

November 14, 2018

News Conference News TCT 2018

PCI vs CABG at 10 Years: MAIN-COMPARE and SYNTAXES Shine Light on Long-term Outcomes

Michael O'Riordan

September 25, 2018

News Conference News ESC 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Michael O'Riordan

August 29, 2018

News Daily News

Hybrid Coronary Revascularization at 5 Years: Similar Outcomes to CABG

Yael L. Maxwell

April 23, 2018

News Daily News

CABG Bests PCI for 5-Year Survival in Biggest Analysis Yet, With Options for Left Main Disease

Yael L. Maxwell

March 08, 2018

News Daily News

Diabetes, Multivessel CAD, and LV Dysfunction? Registry Analysis Gives CABG the Edge Over PCI

Michael O'Riordan

February 20, 2018

News Daily News

Prior PCI Does Not Affect Early CABG Outcomes: Registry and Meta-analysis

Leah Lawrence

February 16, 2018

News Daily News

CABG Results in Better Long-term Outcomes Than PCI for Younger Patients With Three-Vessel Disease

Yael L. Maxwell

February 06, 2018

News Features

Cardiologists Treating Syrian Refugees Call Missions an ‘Addictive’ Passion That Saves Lives

Yael L. Maxwell

January 12, 2018

News Industry News

Oceanus 14 Pro, PTA balloon catheter receives CE Mark Approval

December 20, 2017

News Daily News

PCI Comparable to CABG in Left Main Coronary Disease: Meta-analysis

Michael O'Riordan

December 14, 2017

News Opinion Off Script TCT 2017

Off Script: Focusing on the Future

Kwan S. Lee

October 31, 2017

News Conference News TCT 2017

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

Michael O'Riordan

October 30, 2017

News Industry News

RE-DUAL PCI™ Results Offer Favorable New Safety Data on Pradaxa®

August 28, 2017

News Conference News ESC 2017

CABG Appears Superior to PCI for Patients With Type 1 Diabetes, Multivessel Disease

Todd Neale

August 26, 2017

News Industry News

FDA Grants Fast Track Designation To Angionetics' Generx Product Candidate, A One-Time Gene Therapy For Coronary Heart Disease

February 07, 2017

Advertisement

Intact Vascular’s Tack Endovascular System® Receives FDA Approval

CABG vs PCI in Left Main Disease: The Debate Continues

Robocath obtains CE marking for R-One™, its robotic-assisted solution for treating coronary diseases

Top News in Coronary Artery Disease: 2018

Long-term FREEDOM: At Nearly 8 years, CABG Maintains Mortality Benefit Over PCI

PCI vs CABG at 10 Years: MAIN-COMPARE and SYNTAXES Shine Light on Long-term Outcomes

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Hybrid Coronary Revascularization at 5 Years: Similar Outcomes to CABG

CABG Bests PCI for 5-Year Survival in Biggest Analysis Yet, With Options for Left Main Disease

Diabetes, Multivessel CAD, and LV Dysfunction? Registry Analysis Gives CABG the Edge Over PCI

Prior PCI Does Not Affect Early CABG Outcomes: Registry and Meta-analysis

CABG Results in Better Long-term Outcomes Than PCI for Younger Patients With Three-Vessel Disease

Cardiologists Treating Syrian Refugees Call Missions an ‘Addictive’ Passion That Saves Lives

Oceanus 14 Pro, PTA balloon catheter receives CE Mark Approval

PCI Comparable to CABG in Left Main Coronary Disease: Meta-analysis

Off Script: Focusing on the Future

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

RE-DUAL PCI™ Results Offer Favorable New Safety Data on Pradaxa®

CABG Appears Superior to PCI for Patients With Type 1 Diabetes, Multivessel Disease

FDA Grants Fast Track Designation To Angionetics' Generx Product Candidate, A One-Time Gene Therapy For Coronary Heart Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content